in preventing CAUTI
UroShield - Reducing Catheter Associated Infections
UroShield uses breakthrough ultrasound nano-technology to prevent Catheter-Associated Urinary Tract Infections in patients with long-term indwelling urinary catheters
See how UroShield works
UroShield is a small, external medical device that has been developed to prevent bacterial biofilm formation on both urethral and suprapubic catheters by means of low-frequency/low-intensity ultrasound waves that it generates.
The action of the ultrasonic waves on the surfaces of the catheter interfere with the attachment of bacteria, prevent infections developing, reduce catheter encrustations and blockages and decrease or eliminate the need for antibiotics. In addition, UroShield decreases the pain, discomfort and spasm associated with indwelling urinary catheters. All these characteristics make UroShield a breakthrough device to prevent or treat catheter related harm.
UroShield is revolutionising catheter care, supporting the prevention of Catheter-Associated UTIs in patients with long-term indwelling catheters.
Living with a long-term catheter can cause many problems such as recurrent UTIs, blockages, encrustation, pain and bladder spasms which often result in courses of antibiotics. UroShield is delivering outstanding outcomes for patients in clinical studies and now in hospitals across the UK, with some cases described as ‘life-changing’.
Discover more in our Patient Zone.
UroShield is the first medical device that has been developed to succesfully interfere with the attachment of bacteria, prevent the formation of biofilm, increase antibiotic efficacy and decrease the pain and discomfort associated with urinary catheter use. It can be used with any type of indwelling urinary catheter regardless of material or coating.
We invite you to try the system for yourself with our 30-day CAUTI challenge. You can see for yourself the reduction in hospital admissions, infections and blockages, antibiotic prescriptions, bladder washouts and catheter changes while patients experience an increase in their quality of life.
UroShield is available direct from our online shop at the top of the page, patients should check they are eligible for UroShield in our Patient Zone and consult with their GP prior to purchasing a device.
For clinicians interested in our 30 Day CAUTI Challenge please enquire at the bottom of the page or under our ‘contact us’ tab.
UroShield is available direct from our Online Shop at the top of the page, patients should check they are eligible for UroShield in our Patient Zone and consult with their GP prior to purchasing a device.
For clinicians interested in our 30-day CAUTI Challenge please enquire at the bottom of the page or under our “Contact Us” tab.
The Cost of CAUTI and the Impact of UroShield
The cumulative rate of bacteriuria per day of a fitted catheter, therefore by day 20 EVERY patient with a catheter will have some form of bacterial infection.
reduction of E. coli bloodstream infections. This is the target set by NHS improvement to achieve by 2021. BSI's are potentially life-threatening infections which according to recent studies may contribute to 5,500 annual deaths, reportedly costing the NHS 2.3 billion per annum.
of bloodstream infections are caused by E. coli, which is one of the most common bacteria to cause UTIs. E. coli was responsible for over 35,000 BSIs in 2016 and growing, and predicted to be responsible for 60,000 BSIs by 2020.
of bloodstream infections are due to UTIs, therefore we are able to almost halve BSIs by the prevention of UTIs. Over 50% E. coli BSIs originate from the urogenital tract. UroShield has been shown to help prevent Catheter Associated UTIs so could have a huge role in halving BSIs.
Please see below for the latest articles and news updates
Sound Waves Effectively Assist Antibiotics in Elimination of Pseudomonas aeruginosa Biofilms In vitro
Microbial biofilms are highly refractory to antimicrobials. The aim of this study was to investigate the use of low-frequency vibration therapy (20–40 kHz) on antibiotic-mediated Pseudomonas aeruginosa biofilm eradication.
The most compelling evidence is the interim results from the latest Randomised Controlled Trial in America.
10 patients were monitored after release from A&E with a urinary catheter, the average age was 63.5 (high – 82, low – 27)